ProstaScint (indium labeled capromab pendetide) / Jazz - LARVOL DELTA

"Urologos aperndiendo de medicos nucleres. Prostascint… la edad de piedra del PET PSMA @fabyaber @DBarreiro4 @RomanCarvajal #AUA23" (@UroTeragLATAM)

Urology

Evaluating the Current Role of PSMA PET: Utility, Availability, and Challenges (ASCO Daily News) - "Two urea-based imaging agents have recently been approved by the FDA for initial staging of suspected metastatic disease and for localizing disease when patients experience biochemical recurrence after primary therapy....PSMA PET imaging may prove useful in the diagnosis and treatment of metastatic castration-resistant prostate cancer by assessing a patient's response to therapy and by defining the phenotype of disease."

Online posting

Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends. (PubMed, Cancers (Basel)) - "[In]In-capromab pendetide scintigraphy was a new approach in the management of PCa. Here, we recapitulate the role of targeted functional imaging. We briefly mention the most popular radiotracers, their diagnostic accuracy in the primary staging of PCa, and impact on patient management."

Clinical • Journal • Review • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • MRI

Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer. (PubMed, Cancer Rep (Hoboken)) - "This report discusses in detail the homing moieties used in the development of targeted diagnostic tools for detection of PCa. The merits and demerits of monoclonal antibodies, small molecule ligands, peptides, and aptamers for imaging of PCa and intraoperative guided surgery are extensively analyzed. Among all, urea-based ligands were found to be most successful in preclinical and clinical trials and show a major promise for future commercialization."

Clinical • Journal • Review • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy for Prostate Cancer: Current Status and Perspectives. (PubMed, Cancer Biother Radiopharm) - "Initial development of PSMA-targeted radiopharmaceuticals is based on monoclonal antibodies such as ProstaScint™; however, because small molecules are advantageous due to faster blood clearance and better tumor permeability, the focus of current investigative efforts is therefore switched to developing PSMA inhibitor-based radiopharmaceuticals, as they are typically small molecular agents...In addition, the tracers based on PSMA-617 and PSMA I&T can be labeled with α and β emitters (e.g., Ac, Y, and Lu) as well and serve as a theranostic tool for patients with metastatic prostate cancer. While the clinical impact of such concept remains to be verified, the preliminary results of PSMA molecular radiotherapy are very encouraging. With these in mind, the aim of this article is to provide an overview of the recent advancement of PSMA-targeted radiopharmaceuticals and their clinical applications."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1 • KLK3

Molecular Insight Pharmaceuticals presents clinical oncology data at Society of Nuclear Medicine 2012 Annual Meeting (Marketwire) - Molecular Insight presented non-clinical and clinical data at Society of Nuclear Medicine 2012 Annual Meeting; It included seven oral session & five poster presentations focused on the company's small molecule approach to target radiotherapy and imaging of cancer, with particular emphasis on prostate cancer

Diagnostic • Oncology

Radiotherapy (RT) guided by ultra‐small superparamagnetic iron oxide (USPIO)-contrast MRI staging for patients with advanced or recurrent prostate cancer. (ASCO-GU 2020) - "Prior to USPIO-MRI, 20/69 patients had cN1 disease based on abdominal-pelvic CT/MRI, Bone Scan, Prostascint-scan, and F18 Choline, Axumin or PSMA PET/CT. In this cohort of 69 patients with predominantly recurrent PC, USPIO-directed RT was well-tolerated, feasible and resulted in encouraging biochemical control rates. Research Funding: None."

Clinical • MRI

Radiotherapy (RT) guided by ultra‐small superparamagnetic iron oxide (USPIO)-contrast MRI staging for patients with advanced or recurrent prostate cancer. (ASCO-GU 2020) - "Prior to USPIO-MRI, 20/69 patients had cN1 disease based on abdominal-pelvic CT/MRI, Bone Scan, Prostascint-scan, and F18 Choline, Axumin or PSMA PET/CT. In this cohort of 69 patients with predominantly recurrent PC, USPIO-directed RT was well-tolerated, feasible and resulted in encouraging biochemical control rates. Research Funding: None."

Clinical • MRI

"I didn't see ProstaScint® Scan mentioned in the article...did I miss it?" (@FLescas)